III期非小细胞肺癌的免疫治疗：度伐利尤单抗及其他。
Immunotherapy for Stage III NSCLC: Durvalumab and Beyond.
作者信息
Fitzpatrick Orla, Naidoo Jarushka
机构信息
Department of Oncology, Beaumont Hospital, RCSI University of Health Sciences, Dublin, Ireland.
Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD, 21231, USA.
出版信息
Lung Cancer (Auckl). 2021 Nov 2;12:123-131. doi: 10.2147/LCTT.S305466. eCollection 2021.
Abstract
Immunocheckpoint inhibitors (ICIs) have altered the treatment landscape of a wide range of malignancies, including non-small cell lung cancer (NSCLC). This class of agents inhibits the interaction between PD1 and PDL1, and was shown to be efficacious in the landmark PACIFIC trial with 1 year of maintenance durvalumab (anti-PDL1 antibody). This trial demonstrated that its use as a consolidation treatment given after definitive chemoradiotherapy improved progression free survival and overall survival compared to standard-of-care treatment. In this review, we discuss both clinical trial and real-world data that have been published since PACIFIC that support the use of durvalumab for stage III unresectable NSCLC. In addition, we highlight specific populations that may require special considerations for the use of durvalumab in this setting, such as oncogene-addicted NSCLC, the toxicity of immunotherapy, and future directions in ICI research in stage III NSCLC.
摘要
免疫检查点抑制剂（ICIs）已经改变了包括非小细胞肺癌（NSCLC）在内的多种恶性肿瘤的治疗格局。这类药物可抑制PD1与PDL1之间的相互作用，并且在具有里程碑意义的PACIFIC试验中显示出疗效，该试验使用了1年的维持治疗度伐利尤单抗（抗PDL1抗体）。该试验表明，与标准治疗相比，在确定性放化疗后使用其作为巩固治疗可改善无进展生存期和总生存期。在本综述中，我们讨论了自PACIFIC试验以来已发表的支持度伐利尤单抗用于III期不可切除NSCLC的临床试验和真实世界数据。此外，我们强调了在这种情况下使用度伐利尤单抗可能需要特别考虑的特定人群，例如致癌基因成瘾的NSCLC、免疫疗法的毒性以及III期NSCLC中ICI研究的未来方向。
相似文献
1
Immunotherapy for Stage III NSCLC: Durvalumab and Beyond.III期非小细胞肺癌的免疫治疗：度伐利尤单抗及其他。
Lung Cancer (Auckl). 2021 Nov 2;12:123-131. doi: 10.2147/LCTT.S305466. eCollection 2021.
2
Effectiveness of durvalumab consolidation in stage III non-small-cell lung cancer: focus on treatment selection and prognostic factors.度伐利尤单抗巩固治疗 III 期非小细胞肺癌的疗效：关注治疗选择和预后因素。
Immunotherapy. 2022 Aug;14(12):927-944. doi: 10.2217/imt-2021-0341. Epub 2022 Jul 13.
3
Immune checkpoint-inhibitors and chemoradiation in stage III unresectable non-small cell lung cancer.免疫检查点抑制剂联合放化疗治疗不可切除 III 期非小细胞肺癌。
Lung Cancer. 2019 Aug;134:259-267. doi: 10.1016/j.lungcan.2019.05.027. Epub 2019 May 29.
4
Cost-effectiveness and Budgetary Consequence Analysis of Durvalumab Consolidation Therapy vs No Consolidation Therapy After Chemoradiotherapy in Stage III Non-Small Cell Lung Cancer in the Context of the US Health Care System.在考虑到美国医疗保健系统的情况下，durvalumab 巩固治疗与放化疗后不进行巩固治疗在 III 期非小细胞肺癌中的成本效果和预算后果分析。
JAMA Oncol. 2019 Mar 1;5(3):358-365. doi: 10.1001/jamaoncol.2018.5449.
5
Assessing the Influence of Subsequent Immunotherapy on Overall Survival in Patients with Unresectable Stage III Non-Small Cell Lung Cancer from the PACIFIC Study.评估来自 PACIFIC 研究的不可切除 III 期非小细胞肺癌患者后续免疫治疗对总生存期的影响。
Curr Ther Res Clin Exp. 2021 Aug 12;95:100640. doi: 10.1016/j.curtheres.2021.100640. eCollection 2021.
6
Brief Report: Durvalumab After Chemoradiotherapy in Unresectable Stage III EGFR-Mutant NSCLC: A Post Hoc Subgroup Analysis From PACIFIC.简要报告：放化疗后使用度伐利尤单抗治疗不可切除的 III 期 EGFR 突变 NSCLC：PACIFIC 的事后亚组分析。
J Thorac Oncol. 2023 May;18(5):657-663. doi: 10.1016/j.jtho.2023.02.009. Epub 2023 Feb 24.
7
DUART: durvalumab after radiotherapy in patients with unresectable, stage III NSCLC who are ineligible for chemotherapy.度伐利尤单抗联合放疗用于不可切除的 III 期 NSCLC 患者，这些患者由于不适合化疗而无法接受化疗。
Future Oncol. 2021 Dec;17(34):4657-4663. doi: 10.2217/fon-2021-0952. Epub 2021 Nov 15.
8
Patients with unresectable stage III non-small cell lung cancer eligible to receive consolidation therapy with durvalumab in clinical practice based on PACIFIC study criteria.根据 PACIFIC 研究标准，在临床实践中符合接受度伐利尤单抗巩固治疗条件的不可切除 III 期非小细胞肺癌患者。
Respir Investig. 2019 Sep;57(5):466-471. doi: 10.1016/j.resinv.2019.03.011. Epub 2019 May 16.
9
Outcomes with durvalumab after chemoradiotherapy in stage IIIA-N2 non-small-cell lung cancer: an exploratory analysis from the PACIFIC trial.PACIFIC 试验的探索性分析：放化疗后 durvalumab 治疗 IIIA-N2 期非小细胞肺癌的结果。
ESMO Open. 2022 Apr;7(2):100410. doi: 10.1016/j.esmoop.2022.100410. Epub 2022 Mar 2.
10
Unmet Clinical Need in the Management of Locally Advanced Unresectable Lung Cancer: Treatment Strategies to Improve Patient Outcomes.局部晚期不可切除肺癌管理中的未满足临床需求：改善患者结局的治疗策略。
Adv Ther. 2019 Mar;36(3):563-578. doi: 10.1007/s12325-019-0876-4. Epub 2019 Jan 29.
引用本文的文献
1
High radiation dose in chemoradiotherapy followed by immunotherapy with durvalumab in patients with stage III non-small cell lung cancer does not increase risk for pneumonitis.对于III期非小细胞肺癌患者，在放化疗后使用度伐利尤单抗进行免疫治疗时采用高辐射剂量不会增加肺炎风险。
Strahlenther Onkol. 2025 Jun;201(6):656-665. doi: 10.1007/s00066-025-02369-0. Epub 2025 Feb 13.
2
Predictive Biomarkers and Resistance Mechanisms of Checkpoint Inhibitors in Malignant Solid Tumors.恶性实体瘤中检查点抑制剂的预测生物标志物和耐药机制。
Int J Mol Sci. 2024 Sep 6;25(17):9659. doi: 10.3390/ijms25179659.
3
A Single-Center Experience in Combined Oncological-Surgical Treatment for Resectable Locally Advanced Non-Small Cell Lung Cancer (NSCLC).可切除的局部晚期非小细胞肺癌（NSCLC）联合肿瘤外科治疗的单中心经验
Diseases. 2024 May 12;12(5):98. doi: 10.3390/diseases12050098.
4
Redefining the battle against colorectal cancer: a comprehensive review of emerging immunotherapies and their clinical efficacy.重新定义结直肠癌之战：新兴免疫疗法及其临床疗效的全面综述。
Front Immunol. 2024 Mar 12;15:1350208. doi: 10.3389/fimmu.2024.1350208. eCollection 2024.
5
Circular RNA circ_0000376 promotes paclitaxel resistance and tumorigenesis of non-small cell lung cancer via positively modulating KPNA4 by sponging miR-1298-5p.环状 RNA circ_0000376 通过海绵吸附 miR-1298-5p 正向调控 KPNA4 促进紫杉醇耐药及非小细胞肺癌的发生发展。
Thorac Cancer. 2023 Aug;14(22):2116-2126. doi: 10.1111/1759-7714.14994. Epub 2023 Jul 16.
6
Adverse Events and Tolerability of Combined Durvalumab and Tremelimumab versus Durvalumab Alone in Solid Cancers: A Systematic Review and Meta-Analysis.度伐利尤单抗与曲美木单抗联合使用和单独使用度伐利尤单抗治疗实体癌的不良事件和耐受性：一项系统评价和荟萃分析
Biomedicines. 2022 May 10;10(5):1101. doi: 10.3390/biomedicines10051101.
7
A Comparative and Comprehensive Review of Antibody Applications in the Treatment of Lung Disease.抗体在肺部疾病治疗中的应用：比较与综合综述
Life (Basel). 2022 Jan 17;12(1):130. doi: 10.3390/life12010130.
本文引用的文献
1
SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-Small-Cell Lung Cancer-A Multicenter Single-Arm Phase II Trial.SAKK 16/14：在 IIIA（N2）期非小细胞肺癌患者中，新辅助化疗联合度伐利尤单抗：一项多中心单臂 II 期试验。
J Clin Oncol. 2021 Sep 10;39(26):2872-2880. doi: 10.1200/JCO.21.00276. Epub 2021 Jul 12.
2
Radiation Versus Immune Checkpoint Inhibitor Associated Pneumonitis: Distinct Radiologic Morphologies.放射性肺炎与免疫检查点抑制剂相关性肺炎：不同的影像学形态。
Oncologist. 2021 Oct;26(10):e1822-e1832. doi: 10.1002/onco.13900. Epub 2021 Aug 4.
3
Pembrolizumab Plus Concurrent Chemoradiation Therapy in Patients With Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer: The Phase 2 KEYNOTE-799 Nonrandomized Trial.帕博利珠单抗联合同步放化疗治疗不可切除的局部晚期 III 期非小细胞肺癌：2 期 KEYNOTE-799 非随机试验
JAMA Oncol. 2021 Jun 4;7(9):1-9. doi: 10.1001/jamaoncol.2021.2301.
4
Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1-Positive Advanced NSCLC.KEYNOTE-010 研究：帕博利珠单抗对比多西他赛用于治疗既往接受过治疗、PD-L1 阳性的晚期 NSCLC 的 5 年生存更新。
J Thorac Oncol. 2021 Oct;16(10):1718-1732. doi: 10.1016/j.jtho.2021.05.001. Epub 2021 May 26.
5
Real-world prospective analysis of treatment patterns in durvalumab maintenance after chemoradiotherapy in unresectable, locally advanced NSCLC patients.不可切除局部晚期 NSCLC 患者放化疗后使用度伐利尤单抗维持治疗的真实世界前瞻性分析。
Invest New Drugs. 2021 Aug;39(4):1189-1196. doi: 10.1007/s10637-021-01091-9. Epub 2021 Mar 11.
6
Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial.可切除非小细胞肺癌的新辅助纳武利尤单抗或纳武利尤单抗联合伊匹单抗：Ⅱ期随机 NEOSTAR 试验。
Nat Med. 2021 Mar;27(3):504-514. doi: 10.1038/s41591-020-01224-2. Epub 2021 Feb 18.
7
Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive Chemoradiotherapy.度伐利尤单抗用于放化疗后 III 期 EGFR 突变 NSCLC
J Thorac Oncol. 2021 Jun;16(6):1030-1041. doi: 10.1016/j.jtho.2021.01.1628. Epub 2021 Feb 12.
8
Cost-Effectiveness of Durvalumab After Chemoradiotherapy in Unresectable Stage III NSCLC: A US Healthcare Perspective.无法切除的 III 期非小细胞肺癌放化疗后度伐利尤单抗的成本效益：美国医疗保健视角。
J Natl Compr Canc Netw. 2021 Feb 2;19(2):153-162. doi: 10.6004/jnccn.2020.7621. Print 2021 Feb.
9
Role of Consolidation Durvalumab in Patients With EGFR- and HER2-Mutant Unresectable Stage III NSCLC.巩固性 durvalumab 在 EGFR 和 HER2 突变不可切除 III 期 NSCLC 患者中的作用。
J Thorac Oncol. 2021 May;16(5):868-872. doi: 10.1016/j.jtho.2020.12.020. Epub 2021 Feb 1.
10
Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC-an Update From the PACIFIC Trial.PACIFIC 试验的更新：放化疗后 durvalumab 治疗 III 期非小细胞肺癌的 4 年生存结果
J Thorac Oncol. 2021 May;16(5):860-867. doi: 10.1016/j.jtho.2020.12.015. Epub 2021 Jan 19.
Zotero 插件